Literature DB >> 24671224

JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis.

You Wang1, Ya-Nan Yu, Shu Song, Tie-Jun Li, Jing-Ying Xiang, Hong Zhang, Mu-Dan Lu, Fang Ji, Ling-Qing Hu.   

Abstract

PURPOSE: To elucidate the clinicopathological significance and the role of Jun Activation Domain-Binding Protein 1 (JAB1), Ser10-phosphorylated p27 (p27S10), and total p27 in human hepatocellular carcinoma (HCC) prognosis.
METHODS: We evaluated the expression of JAB1 and p27S10 in tissues by immunohistochemical and immunoblot analyses. p27 Ser10 phosphorylation and Ser10 phosphorylation-dependent p27-JAB1 interaction were demonstrated in proliferating Huh7 cells following transfection of pEGFP-p27WT/p27S10A/p27S10D plasmids and pcDNA3.1-p27WT/p27S10A/p27S10D-Myc plasmids. Univariate and multivariate analysis were used to determine their role in HCC prognosis.
RESULTS: JAB1 and p27S10 are overexpressed in HCC samples compared with paired normal tissues. There was a strong correlation between JAB1 and p27S10 expression (P < 0.001), and expression of both inversely correlated with total p27 levels (P < 0.001). High JAB1 and p27S10 expression correlated with histological grade, vascular invasion, and serum α-fetoprotein (AFP) level (all P < 0.01). Total p27 expression also correlated with histological tumor grade (P = 0.048) and AFP level (P = 0.015). The p27S10(high)/JAB1(high)/p27(1ow) profile was the most reliable indication of poor prognostic. Ser10 phosphorylation increased and total p27 levels decreased in a time-dependent manner in serum-starved Huh7 cells following addition of serum. Immunoprecipitation analysis revealed that p27 Ser-to-Asp substitution at position 10 (S10D) markedly enhanced the interaction between JAB1 and p27, but replacement of S10A reduced binding.
CONCLUSIONS: This study revealed that combined JAB1, p27S10, and total p27 expression may serve as a prognostic marker for HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671224     DOI: 10.1007/s00432-014-1646-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability.

Authors:  N Ishida; M Kitagawa; S Hatakeyama; K Nakayama
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  Two populations of p27 use differential kinetics to phosphorylate Ser-10 and Thr-187 via phosphatidylinositol 3-Kinase in response to fibroblast growth factor-2 stimulation.

Authors:  Jeong Goo Lee; Eunduck P Kay
Journal:  J Biol Chem       Date:  2007-01-05       Impact factor: 5.157

3.  Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.

Authors:  You Wang; Yingying Wang; Jingying Xiang; Fang Ji; Yan Deng; Chunhui Tang; Shuyun Yang; Qinghua Xi; Rong Liu; Wen Di
Journal:  Cancer Lett       Date:  2013-09-07       Impact factor: 8.679

4.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

5.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.

Authors:  K Tomoda; Y Kubota; J Kato
Journal:  Nature       Date:  1999-03-11       Impact factor: 49.962

6.  Decreased morbidity and mortality rates in surgical patients with hepatocellular carcinoma.

Authors:  T Matsumata; T Kanematsu; K Shirabe; T Sonoda; T Furuta; K Sugimachi
Journal:  Br J Surg       Date:  1990-06       Impact factor: 6.939

7.  Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.

Authors:  Xundi Xu; Hirofumi Yamamoto; Masato Sakon; Masayoshi Yasui; Chew Yee Ngan; Hiroki Fukunaga; Tetsushi Morita; Minoru Ogawa; Hiroaki Nagano; Shoji Nakamori; Mitsugu Sekimoto; Nariaki Matsuura; Morito Monden
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

Review 8.  Hepatocellular carcinoma: current management and recent advances.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

9.  Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing.

Authors:  M Shirane; Y Harumiya; N Ishida; A Hirai; C Miyamoto; S Hatakeyama; K Nakayama; M Kitagawa
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more
  5 in total

1.  Evaluation of p27 Expression in Salivary Gland Neoplasms; A Step Forward in Unveiling the Role of p27.

Authors:  Nikhil I Malgaonkar; Abdulwahab Abuderman; M Y Kharma; S A Al-Maweri; N A Alaizari; Ma Altamimi; S Darwish; Bassel Tarakji
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.

Authors:  Naruji Kugimiya; Arata Nishimoto; Tohru Hosoyama; Koji Ueno; Yoshihiro Takemoto; Eijiro Harada; Tadahiko Enoki; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

Review 3.  Targeting the COP9 signalosome for cancer therapy.

Authors:  Wenqi Du; Ruicheng Zhang; Bilal Muhammad; Dongsheng Pei
Journal:  Cancer Biol Med       Date:  2022-03-21       Impact factor: 5.347

4.  Prognostic value of CSN5 in patients with digestive system cancers: a systematic review and meta-analysis.

Authors:  Yonghua Guo; Meng Gao; Ye Yao; Jinghua Li; Xi Chen; Xingxing Wang; Zhang Chen; Yufeng Yuan; Weijie Ma
Journal:  BMC Cancer       Date:  2022-07-23       Impact factor: 4.638

5.  p27(Kip1) and Ser10-phosphorylated p27(Kip1) in breast cancer: clinical significance and expression.

Authors:  Wei Song; Ruilian Xie; Aiyu Zhu; Yumei Xu; Yaqin Shi; Yan Shen; Wenwen Zhang; Fang Yang; Xiaoxiang Guan
Journal:  Onco Targets Ther       Date:  2015-07-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.